Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 21;11(3):500.
doi: 10.3390/vaccines11030500.

Recent Developments in Mpox Prevention and Treatment Options

Affiliations
Review

Recent Developments in Mpox Prevention and Treatment Options

Shiza Malik et al. Vaccines (Basel). .

Abstract

Human mpox is an emerging epidemic in the world. The monkey pox virus (MPXV) belongs to the same family of zoonotic Orthopoxviridae as that of the smallpox virus and exhibits similar clinical symptomology. Information regarding its diagnostics, disease epidemiology, surveillance, preventive methods, and treatment strategies are being collated with time. The purpose of this review is to trace the recent events in the scientific platform that have defined new preventive and treatment strategies against mpox. A methodological approach has been used to gather data from the latest literature to comprehensively overview the emerging treatment options. The results portion will cover details regarding the prevention of mpox. It will also shed light on a brief description of contemporary vaccines and antiviral agents that have been evaluated for their treatment potential since the emergence of the mpox threat. These treatment options are setting the pace for controlling the widespread monkeypox infection. However, the limitations attached to these treatment strategies need to be tackled quickly to increase their efficacy so that they can be deployed on a large scale for the prevention of this epidemic becoming another pandemic in this decade.

Keywords: MPXV; antiviral agents; clinical management; mpox; novel therapeutic; therapeutics; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Ajmera K.M., Goyal L., Pandit T., Pandit R. Monkeypox–An emerging pandemic. IDCases. 2022;29:e01587. doi: 10.1016/j.idcr.2022.e01587. - DOI - PMC - PubMed
    1. Focosi D., Novazzi F., Baj A., Maggi F. Monkeypox: An international epidemic. Rev. Med. Virol. 2022;32:e2392. doi: 10.1002/rmv.2392. - DOI - PubMed
    1. Huang Y., Mu L., Wang W. Monkeypox: Epidemiology, pathogenesis, treatment and prevention. Signal Transduct. Target. Ther. 2022;7:373. doi: 10.1038/s41392-022-01215-4. - DOI - PMC - PubMed
    1. Zambrano P.G., Acosta-España J., Moyano F., Jara J.B.A. Sexually or intimately transmitted infections: A look at the current outbreak of monkeypox in 2022. Travel Med. Infect. Dis. 2022;49:102383. doi: 10.1016/j.tmaid.2022.102383. - DOI - PMC - PubMed
    1. Quarleri J., Delpino M., Galvan V. Monkeypox: Considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience. 2022;44:2095–2103. doi: 10.1007/s11357-022-00611-6. - DOI - PMC - PubMed

LinkOut - more resources